What is Lifesci Capital’s Forecast for RCUS Q2 Earnings?

Arcus Biosciences, Inc. (NYSE:RCUS) – Investment analysts at Lifesci Capital issued their Q2 2026 earnings per share (EPS) estimates for Arcus Biosciences in a research note issued to investors on Thursday, June 4th. Lifesci Capital analyst C. Zhu forecasts that the company will post earnings of ($1.03) per share for the quarter. Lifesci Capital currently has a “Outperform” rating and a $46.00 price objective on the stock. The consensus estimate for Arcus Biosciences’ current full-year earnings is ($3.61) per share. Lifesci Capital also issued estimates for Arcus Biosciences’ Q3 2026 earnings at ($1.02) EPS, Q4 2026 earnings at ($1.07) EPS, FY2026 earnings at ($4.15) EPS, Q1 2027 earnings at ($1.09) EPS, Q2 2027 earnings at ($1.11) EPS, Q3 2027 earnings at ($1.16) EPS, Q4 2027 earnings at ($1.20) EPS, FY2027 earnings at ($4.55) EPS, FY2028 earnings at ($4.52) EPS, FY2029 earnings at ($4.56) EPS and FY2030 earnings at ($4.45) EPS.

RCUS has been the subject of a number of other reports. Leerink Partners set a $47.00 target price on shares of Arcus Biosciences in a research note on Monday, April 20th. Wall Street Zen downgraded shares of Arcus Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. HC Wainwright reiterated a “buy” rating and set a $32.00 price objective on shares of Arcus Biosciences in a report on Monday, March 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Arcus Biosciences in a research report on Monday, April 20th. Finally, Morgan Stanley upped their target price on shares of Arcus Biosciences from $20.00 to $22.00 and gave the stock an “equal weight” rating in a research note on Monday, May 11th. Eight research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Arcus Biosciences currently has an average rating of “Moderate Buy” and an average price target of $35.10.

Arcus Biosciences Stock Performance

Shares of Arcus Biosciences stock opened at $23.16 on Monday. The company has a quick ratio of 4.04, a current ratio of 4.04 and a debt-to-equity ratio of 0.19. The stock’s fifty day moving average is $23.84 and its two-hundred day moving average is $22.85. Arcus Biosciences has a 52 week low of $7.91 and a 52 week high of $28.72. The company has a market capitalization of $2.91 billion, a PE ratio of -7.28 and a beta of 0.85.

Arcus Biosciences (NYSE:RCUS) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($1.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.10). Arcus Biosciences had a negative return on equity of 68.97% and a negative net margin of 156.36%.The business had revenue of $17.00 million for the quarter, compared to the consensus estimate of $29.49 million. During the same period in the prior year, the business posted ($1.14) earnings per share. Arcus Biosciences’s revenue was down 39.3% on a year-over-year basis.

Insiders Place Their Bets

In related news, CAO Alexander Azoy sold 2,562 shares of Arcus Biosciences stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $25.77, for a total value of $66,022.74. Following the completion of the sale, the chief accounting officer directly owned 39,581 shares in the company, valued at $1,020,002.37. The trade was a 6.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Robert C. Goeltz II sold 7,763 shares of the stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $25.63, for a total transaction of $198,965.69. Following the transaction, the chief financial officer owned 84,161 shares in the company, valued at approximately $2,157,046.43. The trade was a 8.45% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Arcus Biosciences

Several hedge funds have recently modified their holdings of RCUS. AQR Capital Management LLC lifted its position in shares of Arcus Biosciences by 253.9% in the 1st quarter. AQR Capital Management LLC now owns 90,954 shares of the company’s stock worth $714,000 after purchasing an additional 65,254 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Arcus Biosciences by 10.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,572 shares of the company’s stock valued at $297,000 after buying an additional 3,565 shares during the period. Millennium Management LLC raised its stake in Arcus Biosciences by 29.2% in the first quarter. Millennium Management LLC now owns 1,194,622 shares of the company’s stock worth $9,378,000 after buying an additional 270,253 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in Arcus Biosciences by 106.2% in the first quarter. Goldman Sachs Group Inc. now owns 914,208 shares of the company’s stock worth $7,177,000 after buying an additional 470,755 shares in the last quarter. Finally, Strs Ohio purchased a new stake in Arcus Biosciences during the first quarter worth $67,000. Hedge funds and other institutional investors own 92.89% of the company’s stock.

Key Arcus Biosciences News

Here are the key news stories impacting Arcus Biosciences this week:

• Positive Sentiment: LifescI Capital maintained an Outperform rating on Arcus Biosciences and set a $46 price target, signaling meaningful upside from current levels.
• Neutral Sentiment: The analyst’s updated forecasts for 2026-2030 remain broadly consistent across periods, suggesting no major near-term change in the long-term view on the company’s earnings trajectory.
• Negative Sentiment: Despite the upbeat rating, Lifesci Capital expects negative EPS in every period it covered, including losses of about ($4.15) in FY2026 and ($4.55) in FY2027, reinforcing concerns about profitability.
• Negative Sentiment: The estimates sit below zero even in later years, with projected losses of roughly ($4.52) in FY2028, ($4.56) in FY2029, and ($4.45) in FY2030, which may be keeping pressure on the stock.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.